Drugs / Neridronate
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT01803360 | Mar → Jul 2013 | osteoarthritis, knee | ASST Gaetano Pini-CTO | Unknown | Met primary |
| Phase 2 | NCT01140321 | Jan 2004 → May 2010 | beta-thalassemia intermedia, beta-thalassemia major, osteoporosis | Ente Ospedaliero Ospedali Galliera | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07210515 | Apr 2026 → Dec 2027 expected | complex regional pain syndrome type 1 | Ambros Therapeutics, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-12-12 | Ambros Therapeutics, Inc. | Regulatory Ambros Therapeutics Launches with $125 Million Series A Financing to Advance Neridronate Through Phase 3 Registrational Program for Complex Regional Pain Syndrome Type 1 ambrostherapeutics.com ↗
Neridronate granted FDA Breakthrough Therapy, Fast-Track, and Orphan Drug designations; pivotal Phase 3 trial planned to start in the first quarter of 2026 |
All press releases naming this drug 3 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neridronate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01803360 ↗ |
| Known as | AMBTX-01 | “Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)” NCT07210515 ↗ |
| Route | Intravenous | “neridronate 100 mg intravenously every 90 d” PMID 22571408 ↗ May 2012 |